Pharmacogenomics Corner

Back to articles

Genetic testing helps predict cardiac risk, statin benefits

May 4, 2015
  • Advising on this article:
  • Mary W. Roederer

KEY POINT

Use of a genetic risk score based on 27 genetic single nucleotide polymorphisms (SNPs) in more than 48,000 primary and secondary prevention patients helped determine who was at increased risk for cardiovascular events and who would benefit the most from statin therapy, according to new data published in Lancet.

REVISIONS

Mega JL et al. Genetic risk, coronary heart disease events, and the clinical benefit of statin therapy: an analysis of primary and secondary prevention trials. Lancet. 2015;[Epub ahead of print].

Schunkert H et al. Statin treatment: can genetics sharpen the focus? Lancet. 2015;[Epub ahead of print].

Recent Articles

2215 Constitution Avenue NW, Washington, DC 20037 Telephone 202-628-4410 Fax 202-783-2351

© 2013 American Pharmacists Association All Rights Reserved.

About the American
Pharmacists Association

The American Pharmacists Association (APhA) is the organization whose members are recognized in society as essential in all patient care settings for optimal medication use that improves health, wellness and quality of life. Through information, education and advocacy, APhA empowers its members to improve medication use and advance patient care.

More info

About APhA DrugInfoLine

APhA DrugInfoLine (ISSN 2162-3015) is a weekly publication of, and is owned and copyrighted by the American Pharmacists Association, the national professional society of pharmacists. Materials in APhA DrugInfoLine do not neccessarily represent the policy, recommendations, or endorsement of APhA. The publisher, authors, editors, reviewers, and contributors have taken care to ensure that the information contained in APhA DrugInfoLine is accurate and current; however, they shall have no ability to any person or entity with regard to claims, losses, or damage caused or alleged to be caused, directly or indirectly by use of any information contained in the publication. All decisions about drug therapy must be based on independent judgement of the clinician.